Everquest Capital Partners takes 0.4% stake in Qkine, life-science protein firm

Published

Everquest Capital Partners entered Qkine Limited’s register with 18,230 ordinary shares, representing a 0.4% stake in the company. No other corporate, fund, trust or nominee entry or exit is reported. Anthemic LLC and O2H Nominees Limited also increased their ordinary holdings, while the register’s total shares rose. The filing date is 10 June 2026, covering 1 June 2025 to 1 June 2026.

Shareholder data

Source: Companies House confirmation statement (CS01) — period to , filed .

Changes in this confirmation statement

TypeShareholderSharesChangeShare classes
New shareholderEVERQUEST CAPITAL PARTNERS18,230
ORDINARY 18,230

Current shareholders (13)

ShareholderTotal sharesShare classes
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE267,317
ORDINARY 267,317
MARTLET CAPITAL LIMITED229,096
ORDINARY 229,096
ANTHEMIC LLC221,055
ORDINARY 221,055
DOWNING HEALTHCARE KNOWLEDGE INTENSIVE EIS FUND217,873
ORDINARY 217,873
O2H NOMINEES LIMITED131,835
ORDINARY 131,835
THAMES VENTURES 2 VCT PLC (DOWNING VCT FUNDS)131,755
ORDINARY 131,755
KCP NOMINEES LTD86,956
ORDINARY 86,956
CPI ENTERPRISES LTD63,317
ORDINARY 63,317
EVERQUEST CAPITAL PARTNERS18,230
ORDINARY 18,230
ZEPPELIN INVESTMENTS PTY LTD16,908
ORDINARY 16,908
DOWNING HEALTHCARE IMPACT EIS FUND15,587
ORDINARY 15,587
AUBIGNY INVESTMENTS PTY LTD13,526
ORDINARY 13,526
WATSON'S BAY INVESTMENTS PTY LTD12,077
ORDINARY 12,077

Share this

Contact the editorial team at editorial@fundingspotter.com